顺铂逆转鼻咽癌紫杉醇耐药分子机制的初步研究
|
摘要
第一章顺铂逆转鼻咽癌紫杉醇耐药细胞系的耐药性
目的：比较顺铂对鼻咽癌细胞CNE-1及其紫杉醇耐药细胞系CNE-1/taxol生长抑制率的差异,观察顺铂对鼻咽癌紫杉醇耐药细胞系CNE-1/taxol耐药性的影响。
方法：以CNE-1和CNE-1/taxol为实验对象,通过集落形成试验检测顺铂对CNE-1和CNE-1/taxol的敏感性；运用流式细胞仪检测顺铂对细胞凋亡的影响；等效剂量分析紫杉醇和顺铂联合作用两种细胞产生的效用。
结果：紫杉醇处理CNE-1和CNE-1/taxol后,其IC50值分别为1.33±0.05nmol/L和11.24±0.51nmol/L,显示CNE-1/taxol的耐药指数为8.43；不同剂量(300nmol/L、600nmol/L、900nmol/L、1200nmol/L和1500nmol/L)的顺铂作用于两种细胞后,通过集落形成实验发现顺铂作用于CNE-1/taxol的IC50值为591.1±23.2 nmol/L,而作用于CNE-1的IC50值为1269.6±52.2 nmol/L,显示出CNE-1/taxol对顺铂的敏感性显著高于CNE-1对顺铂的敏感性(p<0.01)；低剂量顺铂(IC20)预处理细胞后,紫杉醇对CNE-1/taxol生长抑制的IC50值为5.34±0.29nmol/L,耐药指数下降为4.02,其敏感性显著增加(p<0.01),而CNE-1对紫杉醇的敏感性没有因顺铂的预处理发生明显变化(P>0.05)；当紫杉醇和顺铂联合作用CNE-1/taxol, CI值均小于1,表明两药具有协同作用。不同剂量顺铂(300-1500nmol/L)作用于两种细胞后,运用流式细胞仪检测其凋亡率,发现5个浓度顺铂使耐药细胞(CNE-1/taxol)的凋亡率显著高于亲本细胞(CNE-1)的凋亡率(P<0.01)。
结论：紫杉醇耐药细胞系CNE-1/taxol对顺铂的敏感性高于亲本细胞CNE-1对顺铂的敏感性；顺铂能够逆转CNE-1/taxol对紫杉醇的耐药性。
第二章应用基因芯片技术筛选鼻咽癌紫杉醇耐药及耐药逆转相关基因的表达谱
目的：应用基因芯片技术筛选鼻咽癌紫杉醇耐药及耐药逆转相关基因的表达谱,试图发现与鼻咽癌紫杉醇耐药及耐药相关的基因。
方法：使用Affymetrix HG-U133 Plus 2.0基因芯片对紫杉醇和顺铂分别处理前后的CNE-1及CNE-1/taxol细胞进行大规模的基因差异表达的检测,并进行数据分析。
结果：经过多重分析与筛选,297个基因可能与紫杉醇耐药及耐药逆转相关。在耐药细胞系下调、而顺铂使之上调的基因有133个,这些基因涉及到了血管形成、凋亡、细胞生长等方面；在耐药细胞系上调、而顺铂使之下调的基因164个,主要涉及类固醇的合成和代谢,以及细胞的生长和凋亡等方面。其中改变超过5倍以上的基因有TSP1、LAMC2、PSG7、NRG1、KRT14、AKAP12、G0S2、TMEM40、MYEOV、SERPINA3、CFI、MAOA、MYOM2、METTL7A、FOS、NOV、ABP1。通过对已知耐药相关基因的分析,结果显示：
1.具有药物转运作用的ATP结合盒家族中MDR1基因在各样本中都没有出现阳性表达；出现差异表达的家族成员中,有个8基因表达上调,而顺铂处理没有使这8个基因的表达下降。
2.P450家族中CYP1A1在亲本细胞中不表达,在耐药细胞中出现了较强的阳性表达,经紫杉醇处理后,其表达进一步大幅下调,顺铂处理后其表达下调。
3.肿瘤坏死因子家族中在耐药细胞系表达下调的有TNFAIP1、3、6、8和肿瘤坏死因子受体TNFRSF10B、12A、21。其中经顺铂处理后出现逆向表达增强的基因有TNFAIP1、3和TNFRSF12A、21
4. Caspase家族除CASP4在耐药细胞中表达下调,经顺铂处理后,其表达进一步下调,而在紫杉醇作用后,表达出现上调。CASP6在耐药细胞中表达上调,经顺铂处理后,其表达出现了下调,其余的Caspase家族成员的表达变化都不明显或者不表达。
5.与紫杉醇耐药相关的β-微管蛋白同型中除β-微管蛋白Ⅱ出现差异表达外,β-微管蛋白Ⅲ、Ⅵ在各样本中表达差异不明显(p<0.05),β-微管蛋白Ⅰ、Ⅳ在6个样本中都没有出现阳性表达
6.紫杉醇耐药基因TXR1在耐药细胞中表达上调,经紫杉醇和顺铂处理后,其表达变化均不明显。凝血酶敏感蛋白TSP1基因在耐药细胞中表达下调,经紫杉醇处理后,表达进一步下调,但是,经顺铂作用后,其表达出现了明显的上调。
结论：17个显著变化的基因可能与鼻咽癌紫杉醇耐药及耐药逆转相关,如TSP1、LAMC2等。目前认为与紫杉醇耐药相关基因中的ATP-结合盒转运体家族、β微管蛋白都不是CNE-1/taxol耐药性产生过程中的关键因素；凋亡相关基因Caspase家族表达与CNE-1/taxol耐药性无关,而肿瘤坏死因子家族的部分基因可能参与了鼻咽癌紫杉醇耐药；CYP1A1的表达改变可能与CNE-1/taxol的耐药及耐药逆转有一定的相关性。
第三章TXR1/TSP1信号通路与鼻咽癌紫杉醇耐药及耐药逆转的关系
目的：探讨TXR1/TSP1信号通路在鼻咽癌紫杉醇耐药及耐药逆转中的作用。
方法：通过RT-PCR、免疫荧光和western blot,在mRNA及蛋白质水平对基因的表达进行验证,同时,运用不同的药物剂量处理CNE-1和CNE-1/taxol,观察TSP1的表达变化。
结果：通过RT-PCR试验,发现TXR1在CNE-1/taxol的表达大约是CNE-1的7倍；而TSP1在mRNA和蛋白质水平分别下调了8.9和5.6倍；经591.1 nmol/L (IC50)顺铂作用24h后,CNE-1/taxol中TSP1在mRNA水平表达上调了8.7倍,经300 nmol/L-1500 nmol/L顺铂作用后,随着药物浓度的增加,TSP1蛋白的表达随之上调；然而,两种细胞经顺铂作用后,TXR1的表达都没有出现明显的改变。
结论：CNE-1/taxol耐药性的产生可能与TXR1的表达有关,并且是通过下调TSP1的表达实现的；顺铂可能是通过上调TXR1的下游基因TSP1来逆转CNE-1/taxol的耐药性的。
Chapter One Reversal of the taxol-resistant phenotype by cisplatin in nasopharyngeal carcinoma
Object:To compare the difference of cell growth inhibition between taxol-resistance NPC cells and its parental cells treated by cisplatin, and observe if cisplatin reverse the taxol-resistance phenotype in NPC.
Method:A taxol-resistant NPC cell line(CNE-1/taxol) and its parental cell line (CNE-1) were cultured in normal condition. The sensitivity of both CNE-1 and CNE-1/taxol to cisplatin was detected using the colony formation assay. Apoptotic death was measured by flow cytometry. The CI-isobologram was used to analyze the drug combination assays of taxol and cisplatin.
Result:The IC50 value of CNE-1 and CNE-1/taxol was respectively 1.33±0.05nmol/L,11.24±0.51nmol/L when both cell lines treated by taxol. The index of CNE-1/taxol was 8.43. The IC50 value of CNE-1/taxol and CNE-1 was respectively 591.1±23.2 nmol/L and 1269.6±52.2 nmol/L when both cell lines treated by different doses of cisplatin (300nmol/L、600nmol/L、900nmol/L、1200nmol/L and 1500nmol/L). The sensitivity to cisplatin in CNE-1/taxol was significantly higher than in CNE-1 (p<0.01). When the cells were pretreated with low-dose cisplatin (IC20), the growth inhibition rates of taxol in CNE-1 cells remained unchanged, however, the rate significantly increased in CNE-1/taxol cells(p<0.01), its IC50 value was changed to 5.34±0.29nmol/L. The coadministration of taxol and cisplatin produced the synergistic effect in taxol-resistant NPC cells, but only additive effects in parental NPC cells. The apoptotic rate was significantly higher in CNE-1/taxol than in CNE-1 cells when both cell lines were treated by different doses of cisplatin (P＜0.01)
Conclusion:CNE-1/taxol cells were more sensitive to treatment with cisplatin than its parental cells, CNE-1.Cisplatin reversed the taxol-resistant phenotype in NPC cells.
Chapter Two Screening the differential expression of taxol-resistance related genes of nasopharyngeal carcinoma by cDNA microarray
Object:To screen the profiling of gene expression related to taxol resistance and reversal of taxol resistance, and search for genes related to taxol-resistance phenotype.
Method:To detect the differential expression of CNE-1/taxol and CNE-1 treated by taxol and cisplatin using cDNA microarray.
Result:297 genes was traped in our designed criteria through multiple steps. Some of these genes should be taxol-resistant genes.133 genes were down-expressed in CNE-1/taxol, and its expression level could be restored by cisplatin.164 genes were overexpressed in CNE-1/taxol, and its expression level could also be recovered by cisplatin. These genes involved in angiogenesis, cell growth, cell metabolism, apoptosis, etc.17 genes were screened out when the fold change must be more than 5, including TSP1、LAMC2、PSG7、NRG1、KRT14、AKAP12、G0S2、TMEM40、MYEOV、SERPINA3、CFI、MAOA、MYOM2、METTL7A、FOS、NOV、ABP1.
1.Through Analyzing documented drug-resistant genes, MDR1 expression was not detected in all NPC samples. Eight ATP-binding cassette transporters that highly expressed in paclitaxel-resistance nasopharyngeal carcinoma cells were detected. However, the expression of these genes were not increased in CNE-1/taxol cells after treated by IC50 taxol.
2.CYP1A1 of P450 family members was not expressed in CNE-1, but significantly increased expression was found in CNE-1/taxol and these increased expression could be restored by cisplatin.
3.The expression level of 4 genes and 3 receptor genes of tumor necrosis factor family members were decresed in CNE-1/taxol, and restored by cisplatin. These genes included TNFAIP1、3、6、8 and TNFRSF10B、12A、21。
4.The expression of CASP4 was decreased in CNE-1/taxol, but not changed by cisplatin. The other genes of Caspase family members were not significantly changed.
5.The expression ofβ-tubulin I and IV were not detected in all samples. No differential expression was found in P-tubulin III and VI when both CNE/taxol and CNE-1 cells treated or untreated by taxol and cisplatin(p>0.05). The expression ofβ-tubulin II were down-regulated in CNE-1/taxol.
6.The expression of TXR1 was higher in CNE-1/taxol than in CNE-1. TSP1 was obviously down-regulated in CNE-1/taxol compared with CNE-1, and a more significant down-regulation of TSP1 was found when CNE-1/taxol treated by taxol. However, it was greatly up-regulation after treated by cisplatin in CNE-1/taxol.
Conclusion:17 Significant changed genes in CNE-1/taxol may relate to taxol resistance and reversal of taxol resistance in NPC cells, such as TSP1, LAMC2, etc. ATP-binding cassette transporters (including MDR1) were not associated with taxol resistance of NPC, and P-tubulin isotype were not key genes in drug resistance. Caspase family members of apoptotic-related genes were nothing to do with CNE-1/taxol resistance. CYP1A1 may play a role of taxol resistance and reversal of taxol resistance in NPC cells.
Chapter Three The role of TXR1/TSP1 in taxol resistance and reversal of taxol resistance in NPC cells
Object:To understand the role of TXR1/TSP1 in taxol resistance and reversal of taxol resistance in NPC cells.
Method:Both CNE-1/taxol and CNE-1 cells were treated by different doses of taxol and cisplatin. The mRNA expression of genes was determined by RT-PCR, protein western of genes was detected by immunofluorescence and western blot.
Result:Approximate 7-fold increase of TXR1 mRNA expression and 8.9-fold decrease of TSP1 mRNA expression were observed in taxol-resistant cells compared to their parental cells. An 8.7-fold increase in TSP1 mRNA expression was observed in CNE-1/taxol cells exposed to 590 nM cisplatin for 24 hours. An increase in TSP1 protein expression was obtained in a dose-dependent manner after CNE-1/taxol cells were exposed to cisplatin. However, there was no change in TXR1 mRNA expression after both CNE-1 and CNE-1/taxol cells were exposed to cisplatin.
Conclusion:The TXR1/TSP1 regulation pathway may relate to taxol resistance in NPC cells. It was determined that cisplatin reverses drug resistance through the up-regulatin of TSP1 downstream of TXR1.
目的：比较顺铂对鼻咽癌细胞CNE-1及其紫杉醇耐药细胞系CNE-1/taxol生长抑制率的差异,观察顺铂对鼻咽癌紫杉醇耐药细胞系CNE-1/taxol耐药性的影响。
方法：以CNE-1和CNE-1/taxol为实验对象,通过集落形成试验检测顺铂对CNE-1和CNE-1/taxol的敏感性；运用流式细胞仪检测顺铂对细胞凋亡的影响；等效剂量分析紫杉醇和顺铂联合作用两种细胞产生的效用。
结果：紫杉醇处理CNE-1和CNE-1/taxol后,其IC50值分别为1.33±0.05nmol/L和11.24±0.51nmol/L,显示CNE-1/taxol的耐药指数为8.43；不同剂量(300nmol/L、600nmol/L、900nmol/L、1200nmol/L和1500nmol/L)的顺铂作用于两种细胞后,通过集落形成实验发现顺铂作用于CNE-1/taxol的IC50值为591.1±23.2 nmol/L,而作用于CNE-1的IC50值为1269.6±52.2 nmol/L,显示出CNE-1/taxol对顺铂的敏感性显著高于CNE-1对顺铂的敏感性(p<0.01)；低剂量顺铂(IC20)预处理细胞后,紫杉醇对CNE-1/taxol生长抑制的IC50值为5.34±0.29nmol/L,耐药指数下降为4.02,其敏感性显著增加(p<0.01),而CNE-1对紫杉醇的敏感性没有因顺铂的预处理发生明显变化(P>0.05)；当紫杉醇和顺铂联合作用CNE-1/taxol, CI值均小于1,表明两药具有协同作用。不同剂量顺铂(300-1500nmol/L)作用于两种细胞后,运用流式细胞仪检测其凋亡率,发现5个浓度顺铂使耐药细胞(CNE-1/taxol)的凋亡率显著高于亲本细胞(CNE-1)的凋亡率(P<0.01)。
结论：紫杉醇耐药细胞系CNE-1/taxol对顺铂的敏感性高于亲本细胞CNE-1对顺铂的敏感性；顺铂能够逆转CNE-1/taxol对紫杉醇的耐药性。
第二章应用基因芯片技术筛选鼻咽癌紫杉醇耐药及耐药逆转相关基因的表达谱
目的：应用基因芯片技术筛选鼻咽癌紫杉醇耐药及耐药逆转相关基因的表达谱,试图发现与鼻咽癌紫杉醇耐药及耐药相关的基因。
方法：使用Affymetrix HG-U133 Plus 2.0基因芯片对紫杉醇和顺铂分别处理前后的CNE-1及CNE-1/taxol细胞进行大规模的基因差异表达的检测,并进行数据分析。
结果：经过多重分析与筛选,297个基因可能与紫杉醇耐药及耐药逆转相关。在耐药细胞系下调、而顺铂使之上调的基因有133个,这些基因涉及到了血管形成、凋亡、细胞生长等方面；在耐药细胞系上调、而顺铂使之下调的基因164个,主要涉及类固醇的合成和代谢,以及细胞的生长和凋亡等方面。其中改变超过5倍以上的基因有TSP1、LAMC2、PSG7、NRG1、KRT14、AKAP12、G0S2、TMEM40、MYEOV、SERPINA3、CFI、MAOA、MYOM2、METTL7A、FOS、NOV、ABP1。通过对已知耐药相关基因的分析,结果显示：
1.具有药物转运作用的ATP结合盒家族中MDR1基因在各样本中都没有出现阳性表达；出现差异表达的家族成员中,有个8基因表达上调,而顺铂处理没有使这8个基因的表达下降。
2.P450家族中CYP1A1在亲本细胞中不表达,在耐药细胞中出现了较强的阳性表达,经紫杉醇处理后,其表达进一步大幅下调,顺铂处理后其表达下调。
3.肿瘤坏死因子家族中在耐药细胞系表达下调的有TNFAIP1、3、6、8和肿瘤坏死因子受体TNFRSF10B、12A、21。其中经顺铂处理后出现逆向表达增强的基因有TNFAIP1、3和TNFRSF12A、21
4. Caspase家族除CASP4在耐药细胞中表达下调,经顺铂处理后,其表达进一步下调,而在紫杉醇作用后,表达出现上调。CASP6在耐药细胞中表达上调,经顺铂处理后,其表达出现了下调,其余的Caspase家族成员的表达变化都不明显或者不表达。
5.与紫杉醇耐药相关的β-微管蛋白同型中除β-微管蛋白Ⅱ出现差异表达外,β-微管蛋白Ⅲ、Ⅵ在各样本中表达差异不明显(p<0.05),β-微管蛋白Ⅰ、Ⅳ在6个样本中都没有出现阳性表达
6.紫杉醇耐药基因TXR1在耐药细胞中表达上调,经紫杉醇和顺铂处理后,其表达变化均不明显。凝血酶敏感蛋白TSP1基因在耐药细胞中表达下调,经紫杉醇处理后,表达进一步下调,但是,经顺铂作用后,其表达出现了明显的上调。
结论：17个显著变化的基因可能与鼻咽癌紫杉醇耐药及耐药逆转相关,如TSP1、LAMC2等。目前认为与紫杉醇耐药相关基因中的ATP-结合盒转运体家族、β微管蛋白都不是CNE-1/taxol耐药性产生过程中的关键因素；凋亡相关基因Caspase家族表达与CNE-1/taxol耐药性无关,而肿瘤坏死因子家族的部分基因可能参与了鼻咽癌紫杉醇耐药；CYP1A1的表达改变可能与CNE-1/taxol的耐药及耐药逆转有一定的相关性。
第三章TXR1/TSP1信号通路与鼻咽癌紫杉醇耐药及耐药逆转的关系
目的：探讨TXR1/TSP1信号通路在鼻咽癌紫杉醇耐药及耐药逆转中的作用。
方法：通过RT-PCR、免疫荧光和western blot,在mRNA及蛋白质水平对基因的表达进行验证,同时,运用不同的药物剂量处理CNE-1和CNE-1/taxol,观察TSP1的表达变化。
结果：通过RT-PCR试验,发现TXR1在CNE-1/taxol的表达大约是CNE-1的7倍；而TSP1在mRNA和蛋白质水平分别下调了8.9和5.6倍；经591.1 nmol/L (IC50)顺铂作用24h后,CNE-1/taxol中TSP1在mRNA水平表达上调了8.7倍,经300 nmol/L-1500 nmol/L顺铂作用后,随着药物浓度的增加,TSP1蛋白的表达随之上调；然而,两种细胞经顺铂作用后,TXR1的表达都没有出现明显的改变。
结论：CNE-1/taxol耐药性的产生可能与TXR1的表达有关,并且是通过下调TSP1的表达实现的；顺铂可能是通过上调TXR1的下游基因TSP1来逆转CNE-1/taxol的耐药性的。
Chapter One Reversal of the taxol-resistant phenotype by cisplatin in nasopharyngeal carcinoma
Object:To compare the difference of cell growth inhibition between taxol-resistance NPC cells and its parental cells treated by cisplatin, and observe if cisplatin reverse the taxol-resistance phenotype in NPC.
Method:A taxol-resistant NPC cell line(CNE-1/taxol) and its parental cell line (CNE-1) were cultured in normal condition. The sensitivity of both CNE-1 and CNE-1/taxol to cisplatin was detected using the colony formation assay. Apoptotic death was measured by flow cytometry. The CI-isobologram was used to analyze the drug combination assays of taxol and cisplatin.
Result:The IC50 value of CNE-1 and CNE-1/taxol was respectively 1.33±0.05nmol/L,11.24±0.51nmol/L when both cell lines treated by taxol. The index of CNE-1/taxol was 8.43. The IC50 value of CNE-1/taxol and CNE-1 was respectively 591.1±23.2 nmol/L and 1269.6±52.2 nmol/L when both cell lines treated by different doses of cisplatin (300nmol/L、600nmol/L、900nmol/L、1200nmol/L and 1500nmol/L). The sensitivity to cisplatin in CNE-1/taxol was significantly higher than in CNE-1 (p<0.01). When the cells were pretreated with low-dose cisplatin (IC20), the growth inhibition rates of taxol in CNE-1 cells remained unchanged, however, the rate significantly increased in CNE-1/taxol cells(p<0.01), its IC50 value was changed to 5.34±0.29nmol/L. The coadministration of taxol and cisplatin produced the synergistic effect in taxol-resistant NPC cells, but only additive effects in parental NPC cells. The apoptotic rate was significantly higher in CNE-1/taxol than in CNE-1 cells when both cell lines were treated by different doses of cisplatin (P＜0.01)
Conclusion:CNE-1/taxol cells were more sensitive to treatment with cisplatin than its parental cells, CNE-1.Cisplatin reversed the taxol-resistant phenotype in NPC cells.
Chapter Two Screening the differential expression of taxol-resistance related genes of nasopharyngeal carcinoma by cDNA microarray
Object:To screen the profiling of gene expression related to taxol resistance and reversal of taxol resistance, and search for genes related to taxol-resistance phenotype.
Method:To detect the differential expression of CNE-1/taxol and CNE-1 treated by taxol and cisplatin using cDNA microarray.
Result:297 genes was traped in our designed criteria through multiple steps. Some of these genes should be taxol-resistant genes.133 genes were down-expressed in CNE-1/taxol, and its expression level could be restored by cisplatin.164 genes were overexpressed in CNE-1/taxol, and its expression level could also be recovered by cisplatin. These genes involved in angiogenesis, cell growth, cell metabolism, apoptosis, etc.17 genes were screened out when the fold change must be more than 5, including TSP1、LAMC2、PSG7、NRG1、KRT14、AKAP12、G0S2、TMEM40、MYEOV、SERPINA3、CFI、MAOA、MYOM2、METTL7A、FOS、NOV、ABP1.
1.Through Analyzing documented drug-resistant genes, MDR1 expression was not detected in all NPC samples. Eight ATP-binding cassette transporters that highly expressed in paclitaxel-resistance nasopharyngeal carcinoma cells were detected. However, the expression of these genes were not increased in CNE-1/taxol cells after treated by IC50 taxol.
2.CYP1A1 of P450 family members was not expressed in CNE-1, but significantly increased expression was found in CNE-1/taxol and these increased expression could be restored by cisplatin.
3.The expression level of 4 genes and 3 receptor genes of tumor necrosis factor family members were decresed in CNE-1/taxol, and restored by cisplatin. These genes included TNFAIP1、3、6、8 and TNFRSF10B、12A、21。
4.The expression of CASP4 was decreased in CNE-1/taxol, but not changed by cisplatin. The other genes of Caspase family members were not significantly changed.
5.The expression ofβ-tubulin I and IV were not detected in all samples. No differential expression was found in P-tubulin III and VI when both CNE/taxol and CNE-1 cells treated or untreated by taxol and cisplatin(p>0.05). The expression ofβ-tubulin II were down-regulated in CNE-1/taxol.
6.The expression of TXR1 was higher in CNE-1/taxol than in CNE-1. TSP1 was obviously down-regulated in CNE-1/taxol compared with CNE-1, and a more significant down-regulation of TSP1 was found when CNE-1/taxol treated by taxol. However, it was greatly up-regulation after treated by cisplatin in CNE-1/taxol.
Conclusion:17 Significant changed genes in CNE-1/taxol may relate to taxol resistance and reversal of taxol resistance in NPC cells, such as TSP1, LAMC2, etc. ATP-binding cassette transporters (including MDR1) were not associated with taxol resistance of NPC, and P-tubulin isotype were not key genes in drug resistance. Caspase family members of apoptotic-related genes were nothing to do with CNE-1/taxol resistance. CYP1A1 may play a role of taxol resistance and reversal of taxol resistance in NPC cells.
Chapter Three The role of TXR1/TSP1 in taxol resistance and reversal of taxol resistance in NPC cells
Object:To understand the role of TXR1/TSP1 in taxol resistance and reversal of taxol resistance in NPC cells.
Method:Both CNE-1/taxol and CNE-1 cells were treated by different doses of taxol and cisplatin. The mRNA expression of genes was determined by RT-PCR, protein western of genes was detected by immunofluorescence and western blot.
Result:Approximate 7-fold increase of TXR1 mRNA expression and 8.9-fold decrease of TSP1 mRNA expression were observed in taxol-resistant cells compared to their parental cells. An 8.7-fold increase in TSP1 mRNA expression was observed in CNE-1/taxol cells exposed to 590 nM cisplatin for 24 hours. An increase in TSP1 protein expression was obtained in a dose-dependent manner after CNE-1/taxol cells were exposed to cisplatin. However, there was no change in TXR1 mRNA expression after both CNE-1 and CNE-1/taxol cells were exposed to cisplatin.
Conclusion:The TXR1/TSP1 regulation pathway may relate to taxol resistance in NPC cells. It was determined that cisplatin reverses drug resistance through the up-regulatin of TSP1 downstream of TXR1.
引文
[1]Gallimore AP, Nasopharyngeal carcinoma. Clin Oncol,1995,7:388-393
[2]Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet,2005,365(9476): 2041-2054
[3]Min H, Hong M, Ma J. A new staging system for nasopharyngeal carcinoma in China. lnt J Radia Oncol Biol Phys,1994,30(5):1037-1042
[4]Teo PM, Leung SF, Yu P, et al. A comparison of Ho's, International Union Against Cancer, and American Joint Committee stage classification for nasopharyngeal carcinoma. Cancer,1991,68(15):434-439
[5]张有望.鼻咽癌诊断和治疗研究的进展.曹世龙主编.肿瘤学新理论与新技术,上海：上海科技教育出版社.1997,70
[6]闵华庆,洪明晃.鼻咽癌研究进展.中国肿瘤,1993,2(3)：20-22
[7]Cellai E, Chiavacei P, Olmi P, et al. Carcinoma of the Nasopharynx; results of Radiation therapy. Acta Radiol Oncol,1982,21(2):87-91
[8]Cheng SH, Tsai SY, Yen KL, et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol, 2000,18(10):2040-2045
[9]Serin M, Erkal HS, Cakmak A. Radiation therapy and concurrent cisplatin in management of locoregionally advanced nasopharyngeal carcinomas. Acta Oncol,1999,38(8):1031 -1035
[10]Jordan MA, Toso RJ, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci USA,1993,90(20):9552-9556
[11]Leong SS,Wee J, Rajan S, et al. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer,2008,113 (6):1332-1337
[12]Hussain M, Gadgeel S,Kucuk 0, et al. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer,1999,86(11):2364-2369
[13]Tan EH, Khoo KS, Wee J, et al. Phase Ⅱ trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol,1999,10(2):235-237
[14]Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Ann Oncol,1998,9(3):327-329
[15]Yeo W, Leung TW, Chan AT, et al.A phase Ⅱ study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer,1998,34(13):2027-2031
[16]Tan EH, Khoo KS, Wee J, et al. Phase Ⅱ trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma.Ann Oncol,1999,10(2):235-237.
[17]Horwitz SB, Cohen D, Rao S, et al.Taxol:Mechanisms of action and resistance. J Natl Cancer Inst Monogr,1993, (15):55-61
[18]Bradley G, Ling V. P-Glycoprotein, multidrug resistance and tumor progression.'Cancer Metastasis Rev.1994,13(2):223-233
[19]Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with tubulin gene mutations. J Clin Oncol,1999,17(6):1786-1793
[20]Haber M, Burkhart CA, Regl DL, et al. Altered expression of M beta2, the class Ⅱ beta-tubulin isotype, in a murine J7442.2 cell line with a high level of taxol resistance. J Biol Chem,1995,270(52):31269-31275
[21]Lih CJ, Wei W, Cohen SN.TXR1:a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes & Dev,2006,20(15):2082-2095
[22]van Amerongen R, Berns A.TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes & Dev,2006,20(15): 1975-1981
[23]PENG Xiao-wei,HE Guang-xiang, TAN Guo-lin. Expression of ATP-binding cassette transporters in a paclitaxel-resistant nasopharyngeal carcinoma cell line. Chinese Journal of Otorhinolaryngology-Skull Base,2008,14(1):15-20
[24]Pires MM, Emmert D, Hrycyna CA, et al. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol Pharmacol,2009,75(1):92-100
[25]Quan F, Pan C, Ma Q, et al. Reversal effect of resveratrol on multidrug resistance in KBv200 cell line.Biomed Pharmacother,2008,62 (9): 622-629
[26]Li J, Xu LZ, He KL, et al. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Breast Cancer Res,2001,3(4):253-263
[27]Sugimoto Y, Tsukahara S, Imai Y, et al. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.Mol Cancer Ther,2003,2(1):105-112
[28]Chu Yu-min, Tan Guo-lin,Ma Yan-hong. Establishment of a paclitaxel-resistant human nasopharyngeal carcinoma cell line and study of its mechanisms. Chinese Journal of Otorhinolarygology-Skull Base Surgery,2007,13(6):411-414
[29]Chou TC, Talalay P.Analysis of combined drug effects:a new look at a very old problem. Trends Pharmacol Sci,1983,4:450-454
[30]Zhao L, Wientjes MG, Au JL. Evaluation of Combination Chemotherapy: Integration of Nonlinear Regression, Curve Shift, Isobologram, and Combination Index Analyses. Clinical Cancer Research,2004,10 (23): 7994-8004
[31]杨纯正.肿瘤细胞耐药基因研究进展.中国肿瘤,1996,5(7)：15
[32]Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of Vincristine Resistance in P388 Leukemia in Vivo and in Vitro through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil. Cancer Res,1981,41 (5):1967-1972
[33]Solary E, Velay I, Chauffert B, et al. Quinine Circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR. Nouv Rev Fr Hematol,1990,32(5):361-363
[34]Watanabe T, Tsuge H, Oh-Hara T, et al. Comparative study on reversal efficacy of SDZ PSC 83, Cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.Acta Oncol.1995,34(2):235-241
[35]Kirk J, Syed SK, Harris AL, et al. Reversal of P-glycoprotien mediated muhidrug resistance by pure antioestrogens and novel tamoxifen derivatives. Biochem Pharmacol.1994.48:277-282
[36]谭伟欣,黄永明,刘金文.MRP1介导的多药耐药及其逆转剂的研究进展.广东医学,2006,27(9)：1418-1420
[37]Chen B, Jin F, Lu XL, et al. Effect of PKC inhibitor on P-gp expression and drug-resistance in MGC803 cells. Ai Zheng,2004,23:396-400.
[38]Burg D, Filippov DV, Hermanns R, et al. Peptidomimetic glutathione analogues as novel γGT stable GST inhibitors. J Bioorg Med Chem, 2002,10(1):195-205
[39]Silva KL, Vasconcelos FC, Marques-Santos LF, et al. CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype. Leuk Res,2003,27(3):243-251
[40]褚玉敏.人鼻咽癌紫杉醇耐药细胞株CNE-1/Taxol的建立及其机制初探[硕士学位论文].长沙：中南大学,2006
[41]Tan G, Li H, Chen J, et al.Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells. International Journal of Cancer,2002,97:168-172
[42]刘冠媛,江森.人卵巢癌紫杉醇耐药细胞株的建立及紫杉醇联合化疗方案的体外研究[博士学位论文].济南.山东大学.2003
[43]Minderman H, Brooks T,O'Loughlin KL, et al. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel and tRA96023. Cancer Chemotherapy and Pharmacology,2004, 53(5):363-369
[44]Ojima I, Chen J, Sun L, et al. Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem,2008,51 (11):3203-3221
[45]Mostafa E, Nasar MN, Rabie NA, et al. Induction chemotherapy with paclitaxel and cisplatin, followed by concomitant cisplatin and radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. J Egypt Natl Canc Inst,2006,18(4):348-356
[46]He XY, Hu CS, Ying HM, et al. Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol.2010,267(5):773-778
[47]Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased MDR1 expression can precede gene amplification. Science (Wash DC),1986,232(4750):643-645
[48]Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer:role of ATP-dependent transporters. Nat Rev Cancer,2002,2(1):48-58
[49]Shen DW, Goldenberg S,Pastan I, et al. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol,2000,183(1):108-116
[50]Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol,1996,49(2): 311-318
[51]Goto S, Kamada K, Soh Y, et al.Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res, 2002,93(9):1047-1056
[52]Urasaki Y, Laco GS,Pourquier P, et al.Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res,2001,61(5):1964-1969
[53]Reinhold WC, Kouros-Mehr H, Kohn KW, et al. Apoptotic suscepti-bility of cancer cells selected for camptothecin resistance:gene expression profiling, functional analysis and molecular interaction mapping. Cancer Res,2003,63 (5):1000-1011
[54]Lin X, Ramamurthi K, Mishima M, et al. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res, 2001,61 (4):1508-1516
[55]Taverna P, Liu L, Hanson AJ, et al. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol,2000,46(6):507-516
[56]Hotta T, Saito Y, Mikami T, et al. Interrelationship between 06-alkylguanine-DNA alkyltransferase activity and susceptibility to chloroethylnitrosoureas in several glioma cell lines. J Neurooncol, 1993,17(1):1-8
[57]Shiloh Y. ATM and ATR:networking cellular responses to DNA damage Curr Opin Genet Dev,2001,11(1):71-77
[58]Watanabe T, Tsuge H, Oh- Hara T, et al. Comparative study on reversal
efficacy of SDZ PSC 833, Cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol,1995,34(2):235-241
[59]Gillet JP, Efferth T, Steinbach D, et al.Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res.2004 Dec 15:64(24):8987-93.
[60]Kumar A, Soprano DR, Parekh HK. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Cancer Res.2001 Oct 15:61(20):7552-5
[61]Biedler JL. Genetic aspects of multidrug resistance. Cancer,1992,70 (6 Suppl):1799-1809
[62]Dumontet C, Duran GE, Steger KA, et al. Resistance mechanisms in human sarcoma mutants'derived by single-step exposure to paclitaxel (Taxol).Cancer Res,1996,56(5):1091-1097
[63]Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking MDR1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A,1997,94(8):4028-4033
[64]Childs S, Yeh RL, Hui D, et al. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res,1998,58(18):4160-4167
[65]Kavallaris M. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anti-cancer Drugs,1997, 8(1):17-25
[66]Ohta SK, Nishio N, Kubota T, et al. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res, 1994,85(3):290-297
[67]Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest,1997,100(5):1282-1293
[68]Juliano RL, Ling VA. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys
Acta,1976,455(1):152-162
[69]Riordan JR, Deuchars K, Kartner N, et al. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines Nature,1985,316 (6031):817-819
[70]Kartner N,Evernden-Porelle D,Bradley G, et al. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature,1985,31 (6031):820-823
[71]Roninson IB, Chin JE, Choi K, et al. Isolation of human MDR DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA,1986,83(12):4538-4542
[72]Atul Kumar, Dianne R Soprano, Hemant K Parekh. Cross-Resistance to the Synthetic Retinoid CD437 in a Paclitaxel-resistant Human Ovarian Carcinoma Cell L ine Is Independent of the Overexpression of Retinoic Acid Receptor-γ 1. Cancer Res,2001,61(20):7552-7555
[73]Kang HC, Kim IJ, Park JH, et al. Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays. Clin Cancer Res,2004,10(1Pt1):272-284
[74]Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995, 332(15):1004-1014
[75]Yu LJ, Matias J, Scudiero DA, et al. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos,2001, 29(3):304-312
[76]Stein U, Walther W, Lauren M, et al. Tumor necrosis factor alpha and expression of the multidrug resistance-associated genes LRP and MRP. JNCI.1997,89(11):807-813
[77]Alphonse G, Bionda C, Aloy MT, et al. Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels. Oncogene,2004,23(15):2703-2715
[78]Roy S, Bayly CI, Gareau Y, et al. Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc Natl Acad Sci USA,2001,98(11):6132-6137
[79]Jordan MA, Wilson L. Microtubules and Actin Filaments:Dynamic Targets for Cancer Chemotherapy. Curr Opin Cell Biol,1998,10(1),123-130
[80]Wilson L,Jordan MA.Microtubule dynamics:Taking aim at a moving target. Chem Biol,1995,2(9):569-573
[81]Jordan MA, Wendell K, Gardiner S, et al.Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res,1996,56(4):816-825
[82]Rao S, Krauss NE, Heerding JM, et al.3'-(p-azidobenzamido) taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem,1994,269(5):3132-3134
[83]Preisler VK, Wuck D, Stopper H, et al. Combination of paclitaxel and radiation:genotoxicity in vitro in four mammalian cell lines. Cancer Lett,1999,145(1-2):29-33
[84]Burkhart CA, Kavallaris M, Band Horwitz S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta, 2001,1471(2):01-9
[85]Jaffrezou JP, Dumontet C, Derry B, et al. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res,1995,7(10-11):517-527
[86]Ranganathan S, Benetatos CA, Colarusso PJ, et al. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer,1998,77(4):562-566
[87]Kavallaris M, Kuo DY, Burkhart CA, et al.Taxol-resistant epithelid ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest,1997,100(5):1282-1293
[88]陈杰,钱桂生,黄桂君,等.人肺腺癌多药耐药细胞系的建立及其生物学特征.第三军医大学学报,2001,23(2)：135-137
[89]Baeniziger NL, Brodic GN. Majerus PW. A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci,1971,68(1):240-243
[90]Lawler J, Hynes RO. The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol,1986,103(5):1635-1648
[91]Liu P, Wang Y, Yang RC, et al. Adenovirus-mediated gene therapy with all antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leuk Res,2003,27(8):701-708
[92]Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospon-din-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol,1999,155(2):441-452
[93]Miao WM, Seng WL, Duquette M, et al.Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res,2001,61 (21):7830-7839
[94]Rofstad EK, Henriksen K, Galappathi K, et al. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res,2003, 63(14):4055-4061
[95]Li K,Yang M, Yuen PM, et al.Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and caspase-3. Int J Mol Med,2003,12(6):995-1001
[96]Luo JC, Yamaguchi S,Shinkai A, et al. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res,1998,58(12):2652-2660
[97]Dameron KM, Volpert OV, Tainsky MA, et al. Control of an giogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science,1994, 265(5178):1582-1584
[98]Peng X, Li W, Tan G. Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression. Anticancer Drugs,2010,21 (4):381-388
[1]杨纯正.肿瘤细胞耐药基因研究进展.中国肿瘤,1996,5(7)：15
[2]Shen DW, FojoA, Chin JE, et al. Human multidrug-resistant cell lines: increased MDR1 expression can precede gene amplification. Science (Wash DC),1986,232(4750):643-645
[3]Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer:role of ATP-dependent transporters. Nat Rev Cancer,2002,2(1):48-58
[4]Shen DW, Goldenberg S, Pastan I, et al. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol,2000,183(1):108 -116
[5]Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol,1996,49(2): 311-318
[6]Goto S, Kamada K, Soh Y,et al.Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res, 2002,93 (9):1047-1056
[7]Urasaki Y, Laco GS, Pourquier P, et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res,2001,61 (5):1964-1969
[8]Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res,1996,56(21):4881-4886
[9]Lin X, Ramamurthi K, Mishima M, et al. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res,2001, 61(4):1508-1516
[10]Taverna P, Liu L, Hanson AJ, et al. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol,2000,46(6):507-516
[11]Hott a T, Saito Y, Mikami T, et al. Interrelationship between 06-alkylguanine-DNA alkyltransferase activity and susceptibility to chloroethylnitrosoureas in several glioma cell lines.J Neurooncol, 1993,17(1):1-8
[12]Shiloh Y. ATM and ATR:networking cellular responses to DNA damage. Curr Opin Genet Dev,2001,11(1):71-77
[13]Watanabe T, Tsuge H, Oh-Hara T, et al. Comparative study on reversal efficacy of SDZ PSC 833, Cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol,1995,34(2):235-241
[14]胡振.肿瘤多药耐药逆转剂的研究进展.药学进展,2002,26(3)：129-133
[15]Tsuruo T, Iida H, Tsukagoshi S,et al. Overcoming of Vincristine Resistance in P388 Leukemia in Vivo and in Vitro through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil. Cancer Res,1981,41 (5):1967-1972
[16]Solary E, Velay I, Chauffert B, et al. Quinine Circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR. Nouv Rev Fr Hematol,1990,32(5):361-363
[17]Solary E, Caillot D, chauffert B, et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and Cytarabine for the treatment of acute leukema. J Clin Oncol,1992,10 (5):1730-1735
[18]Watanabe T, Tsuge H, Oh-Hara T, et al. Comparative study on reversal efficacy of SDZ PSC 83, Cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol,1995,34(2):235-241
[19]Kirk J, Syed SK. Harris AL. et al. Reversal of P-glycoprotien mediated muhidrug resistance by pure antioestrogens and novel tamoxifen derivatives. Biochem Pharmacol,1994,48:277-282
[20]谭伟欣,黄永明,刘金文.MRP1介导的多药耐药及其逆转剂的研究进展.广东医学,2006,27(9)：1418-1420
[21]CHEN B, JIN F, LU XL, et al. Effect of PKC inhibitor on P-gp expression and drug-resistance in MGC803 cells. Ai Zheng,2004,23:396-400.
[22]Burg D, Filippov DV, Hermanns R, et al. Peptidomimetic glutathione analogues as novel γGT stable GST inhibitors. J Bioorg Med Chem, 2002,10 (1):195-205
[23]Silva KL, Vasconcelos FC, Marques-Santos LF, et al. CPT-11 induced cell death in leukemic cells is not affected by the MDR phenotype. Leuk Res,2003,27 (3):243-251
[24]Wilson WH, Bates S, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol,1995,13 (8):1995-2004
[25]Pascaud C, Garrigos M, Orlowski S. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J.1998,15,333 (Pt 2):351-358
[26]Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T. Comparative study on reversal efficacy of SDZ PSC833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo Acta Oncol. 1995,34(2):235-341
[27]Lo YL, Liu FI, Yang JM, et al. Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid. Anti Cancer Res,2001,21 (1A):445-450
[28]孙士勇,韩锐.谷胱甘肽S-转移酶与肿瘤防治.国外医学药学分册,1992,19(2)：66-71
[29]胡军,赵瑾瑶,杨佩满,等.β-榄香烯乳剂逆转多药耐药细胞株MCF-7/ADM对阿霉素耐药性研究.中国微生物学杂志,2003,14(4)：214-215
[30]关松磊.关于卵巢癌的蛋白质组学和姜黄素的体外抑制研究：[硕士学位论文].吉林：吉林大学药学院,2007
[31]徐峰,蔡卓夫.肿瘤耐药逆转剂研究进展.中南药学,2004,2(5)：301- 303
[32]王宝成,郭军,顾广玉,等.切割MDR1 RNA的核酶(Ribozyme)对肝癌多药耐药细胞株BEL-7402/DOX化疗耐药性的逆转作用.中国肿瘤生物治疗杂志,1997,4(2)：106-109
[33]Huesker M, Folmer Y, Schneider M, et al. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes. Hepatology,2002,36 (4 Pt1):874-884
[34]Kostenko EV, Laktionov PP, Vlassov VV, et al. Downregulation of PGY1/ MDR1 mRNA level in human KB cells by antisense oligonucleotide conjugates:RNA accessibility in vitro and intracellular antisense activity. Biochim Biophys Acta,2002,1576 (1-2):143-147
[35]Nieth C, Priebsch A, Stege A, et al. Modulation of the classical multi drug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett, 2003,545 (2-3):144-150
[36]Caldas H, Holloway MP, Hall BM, et al. Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo. Med Genet,2006,43 (2):119-128
[37]Yuan J, Kramer A, Matthess Y, et al. Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene,2006,25 (12):1753-1762
[38]Zou W, Yang H, Hou XH, et al. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett,2007,248 (2):211-218
[39]Pichler A, Zelcer N, Prior JL, et al. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res,2005,11 (12): 4487-4494
[40]Duan ZF, Katherine AB, Michael VS. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther, 2004,3 (7):833-838
[41]Anke W, Alexandra S, Yutaka M, et al. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther,2004, 11 (11):699-706
[42]Sun YL, Zhou GY, Li KN, et al. Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells. Neoplasma,2006,53 (1):1-8
[43]Kankesan J, Vanama R, Yusuf A, et al. Effect of P53, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats. Carcinogenesis,2004,25 (3):425-430
[44]Rago RP, Einstein A Jr, Lush R, et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol,2003,51 (4):297-305
[45]Bentires AM, Barbu V, Fillet M, et al. NF-kappa B transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene,2003,22 (1):90-97
[46]Minderman H,O'Loughlin KL, Pendyala L, et al. VX-710 (Biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-Glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res,2004,10 (5): 1826-1834
[47]魏志霞,田韧,端木中.α-干扰素对肝癌多药耐药株SMMC-7221/ADM的逆转及其机制研究.临床肿瘤学杂志,2001,6(4)：339-341
[48]Ghetie MA, Marches R, Kufert S, et al. An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line. Blood,2004,104 (1): 178-183
[49]Ghetie MA, Crank M, Kufert S, et al. Rituximab but not Other anti-CD20 Antibodies Reverses Multidrug Resistance in 2 B lymphoma Cell Lines, Blocks the Activity of P-glycoprotein (P-gp), and Induces P-gp to Translocate out of Lipid Rafts. J Immunother(1997),2006,29 (5): 536-544
[50]Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22 Characterization of in Vitro Properties. Clin Cancer Res,2003,9 (10):3982-3990
[51]Holliger P, Prospero T, Winter G. "Diabodies" : small bivalent antibody fragment. Cancer Immunol Immunother,1997,45 (2):128-130
[52]Zhu ZP, Zapata G, Shalaby R, et al. High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology,1996,14 (2):192-196
[53]Xu YF, Yang CZ, Zhu ZP. Bispecific antibody and its clinical application in cancer. Chinese Science Bulletin,2001,46 (5):353-358
[54]秦岚,赵艳津,高瀛岱,等.抗P-gp/抗CD3微型双功能抗体在小鼠体内性质的研究.天津医药,2006,34(9)：625-627
[55]Niethammer AG, Wodrich H, Loeffier M. Multidrug Resistance-1(MDR-1):a new target for T cell-based immunotherapy FASEB J,2005,19 (1):158-159
[56]Kolberg A, Rosa TG, Puhl MT, et al. Low expression of MRP1/GS-X pump ATPase in lymphocytes of Walker 256 tumour-bearing rats is associated with cyclopentenone prostaglandin accumulation and cancer immunodeficiency. Cell Biochem Funct,2006,24 (1):23-25
[57]Rago RP, Einstein AJR, Lush R, et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol,2003,51 (4):297-305
[58]Atkins MB, Regan M, Mc DD. Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma. Cancer Res,2004,10 (18):6342s-6346s
[59]Marks DC, BelovL R, Davey MW, et al. The MTT cell viability assay for cytotoxicity testing in multidrug-resistance human Leukemic ceils. Leuk Res,1992,16 (12):1165-1173
[60]Azuma E, Masuda S, Qi J, et al. Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias. Eur J Haematol,1997,59 (3):14-19
[61]Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase Ⅰ is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol,2004,10 (8):1146-1151
[62]冷卫东,王大章,冯戈,等.热疗对舌鳞癌Tca8113细胞及其耐药细胞株耐药性的影响.华西口腔医学杂志,2006,24(5)：447-450
[63]Walther W, Arlt F, Fichtner I, et al. Heat-inducible in vivo gene therapy of colon carcinoma by human MDR1 promoter-regulated tumor necrosis factor-alpha expression. Mol Cancer Ther,2007,6 (1):236-243
[64]邢益阳.中药逆转肿瘤多药耐药的研究进展.中医药临床杂志,2007,19(1)：91-93
[65]李宏建,李贵海,孙付军,等.苦参碱对肿瘤细胞获得性多药耐药的逆转作用.中国医院药学杂志,2005,25(5)：389-391
[66]Choi SU, Park SH, Kim KH. The bisbenzylisoquinoline aloids, tetran dine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anti Cancer Drugs,1998,9 (3):255-261
[67]Yoshikawa M, Ikegami Y, Hayasaka S, et al. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer,2004,110 (6):921-927
[68]Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550:a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res,2001,7 (5):1429-1437
[69]Minderman H, Brooks T, O' Loughlin KL, et al. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel and tRA96023. Cancer Chemotherapy and Pharmacology,2004,53 (5):363-369
[70]Ojima I, Chen J, Sun L, et al. Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem,2008,51 (11): 3203-3221
[71]Aoki Y, Kurata H, Watanabe M, et al. Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer. Am J Clin Oncol 2004; 27 (5):461-464
[72]Peng X, Li W, Tan G. Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression. Anticancer Drugs,2010,21 (4):381-388
[2]Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet,2005,365(9476): 2041-2054
[3]Min H, Hong M, Ma J. A new staging system for nasopharyngeal carcinoma in China. lnt J Radia Oncol Biol Phys,1994,30(5):1037-1042
[4]Teo PM, Leung SF, Yu P, et al. A comparison of Ho's, International Union Against Cancer, and American Joint Committee stage classification for nasopharyngeal carcinoma. Cancer,1991,68(15):434-439
[5]张有望.鼻咽癌诊断和治疗研究的进展.曹世龙主编.肿瘤学新理论与新技术,上海：上海科技教育出版社.1997,70
[6]闵华庆,洪明晃.鼻咽癌研究进展.中国肿瘤,1993,2(3)：20-22
[7]Cellai E, Chiavacei P, Olmi P, et al. Carcinoma of the Nasopharynx; results of Radiation therapy. Acta Radiol Oncol,1982,21(2):87-91
[8]Cheng SH, Tsai SY, Yen KL, et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol, 2000,18(10):2040-2045
[9]Serin M, Erkal HS, Cakmak A. Radiation therapy and concurrent cisplatin in management of locoregionally advanced nasopharyngeal carcinomas. Acta Oncol,1999,38(8):1031 -1035
[10]Jordan MA, Toso RJ, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci USA,1993,90(20):9552-9556
[11]Leong SS,Wee J, Rajan S, et al. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer,2008,113 (6):1332-1337
[12]Hussain M, Gadgeel S,Kucuk 0, et al. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer,1999,86(11):2364-2369
[13]Tan EH, Khoo KS, Wee J, et al. Phase Ⅱ trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol,1999,10(2):235-237
[14]Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Ann Oncol,1998,9(3):327-329
[15]Yeo W, Leung TW, Chan AT, et al.A phase Ⅱ study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer,1998,34(13):2027-2031
[16]Tan EH, Khoo KS, Wee J, et al. Phase Ⅱ trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma.Ann Oncol,1999,10(2):235-237.
[17]Horwitz SB, Cohen D, Rao S, et al.Taxol:Mechanisms of action and resistance. J Natl Cancer Inst Monogr,1993, (15):55-61
[18]Bradley G, Ling V. P-Glycoprotein, multidrug resistance and tumor progression.'Cancer Metastasis Rev.1994,13(2):223-233
[19]Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with tubulin gene mutations. J Clin Oncol,1999,17(6):1786-1793
[20]Haber M, Burkhart CA, Regl DL, et al. Altered expression of M beta2, the class Ⅱ beta-tubulin isotype, in a murine J7442.2 cell line with a high level of taxol resistance. J Biol Chem,1995,270(52):31269-31275
[21]Lih CJ, Wei W, Cohen SN.TXR1:a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes & Dev,2006,20(15):2082-2095
[22]van Amerongen R, Berns A.TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes & Dev,2006,20(15): 1975-1981
[23]PENG Xiao-wei,HE Guang-xiang, TAN Guo-lin. Expression of ATP-binding cassette transporters in a paclitaxel-resistant nasopharyngeal carcinoma cell line. Chinese Journal of Otorhinolaryngology-Skull Base,2008,14(1):15-20
[24]Pires MM, Emmert D, Hrycyna CA, et al. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol Pharmacol,2009,75(1):92-100
[25]Quan F, Pan C, Ma Q, et al. Reversal effect of resveratrol on multidrug resistance in KBv200 cell line.Biomed Pharmacother,2008,62 (9): 622-629
[26]Li J, Xu LZ, He KL, et al. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Breast Cancer Res,2001,3(4):253-263
[27]Sugimoto Y, Tsukahara S, Imai Y, et al. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.Mol Cancer Ther,2003,2(1):105-112
[28]Chu Yu-min, Tan Guo-lin,Ma Yan-hong. Establishment of a paclitaxel-resistant human nasopharyngeal carcinoma cell line and study of its mechanisms. Chinese Journal of Otorhinolarygology-Skull Base Surgery,2007,13(6):411-414
[29]Chou TC, Talalay P.Analysis of combined drug effects:a new look at a very old problem. Trends Pharmacol Sci,1983,4:450-454
[30]Zhao L, Wientjes MG, Au JL. Evaluation of Combination Chemotherapy: Integration of Nonlinear Regression, Curve Shift, Isobologram, and Combination Index Analyses. Clinical Cancer Research,2004,10 (23): 7994-8004
[31]杨纯正.肿瘤细胞耐药基因研究进展.中国肿瘤,1996,5(7)：15
[32]Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of Vincristine Resistance in P388 Leukemia in Vivo and in Vitro through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil. Cancer Res,1981,41 (5):1967-1972
[33]Solary E, Velay I, Chauffert B, et al. Quinine Circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR. Nouv Rev Fr Hematol,1990,32(5):361-363
[34]Watanabe T, Tsuge H, Oh-Hara T, et al. Comparative study on reversal efficacy of SDZ PSC 83, Cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.Acta Oncol.1995,34(2):235-241
[35]Kirk J, Syed SK, Harris AL, et al. Reversal of P-glycoprotien mediated muhidrug resistance by pure antioestrogens and novel tamoxifen derivatives. Biochem Pharmacol.1994.48:277-282
[36]谭伟欣,黄永明,刘金文.MRP1介导的多药耐药及其逆转剂的研究进展.广东医学,2006,27(9)：1418-1420
[37]Chen B, Jin F, Lu XL, et al. Effect of PKC inhibitor on P-gp expression and drug-resistance in MGC803 cells. Ai Zheng,2004,23:396-400.
[38]Burg D, Filippov DV, Hermanns R, et al. Peptidomimetic glutathione analogues as novel γGT stable GST inhibitors. J Bioorg Med Chem, 2002,10(1):195-205
[39]Silva KL, Vasconcelos FC, Marques-Santos LF, et al. CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype. Leuk Res,2003,27(3):243-251
[40]褚玉敏.人鼻咽癌紫杉醇耐药细胞株CNE-1/Taxol的建立及其机制初探[硕士学位论文].长沙：中南大学,2006
[41]Tan G, Li H, Chen J, et al.Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells. International Journal of Cancer,2002,97:168-172
[42]刘冠媛,江森.人卵巢癌紫杉醇耐药细胞株的建立及紫杉醇联合化疗方案的体外研究[博士学位论文].济南.山东大学.2003
[43]Minderman H, Brooks T,O'Loughlin KL, et al. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel and tRA96023. Cancer Chemotherapy and Pharmacology,2004, 53(5):363-369
[44]Ojima I, Chen J, Sun L, et al. Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem,2008,51 (11):3203-3221
[45]Mostafa E, Nasar MN, Rabie NA, et al. Induction chemotherapy with paclitaxel and cisplatin, followed by concomitant cisplatin and radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. J Egypt Natl Canc Inst,2006,18(4):348-356
[46]He XY, Hu CS, Ying HM, et al. Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol.2010,267(5):773-778
[47]Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased MDR1 expression can precede gene amplification. Science (Wash DC),1986,232(4750):643-645
[48]Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer:role of ATP-dependent transporters. Nat Rev Cancer,2002,2(1):48-58
[49]Shen DW, Goldenberg S,Pastan I, et al. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol,2000,183(1):108-116
[50]Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol,1996,49(2): 311-318
[51]Goto S, Kamada K, Soh Y, et al.Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res, 2002,93(9):1047-1056
[52]Urasaki Y, Laco GS,Pourquier P, et al.Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res,2001,61(5):1964-1969
[53]Reinhold WC, Kouros-Mehr H, Kohn KW, et al. Apoptotic suscepti-bility of cancer cells selected for camptothecin resistance:gene expression profiling, functional analysis and molecular interaction mapping. Cancer Res,2003,63 (5):1000-1011
[54]Lin X, Ramamurthi K, Mishima M, et al. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res, 2001,61 (4):1508-1516
[55]Taverna P, Liu L, Hanson AJ, et al. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol,2000,46(6):507-516
[56]Hotta T, Saito Y, Mikami T, et al. Interrelationship between 06-alkylguanine-DNA alkyltransferase activity and susceptibility to chloroethylnitrosoureas in several glioma cell lines. J Neurooncol, 1993,17(1):1-8
[57]Shiloh Y. ATM and ATR:networking cellular responses to DNA damage Curr Opin Genet Dev,2001,11(1):71-77
[58]Watanabe T, Tsuge H, Oh- Hara T, et al. Comparative study on reversal
efficacy of SDZ PSC 833, Cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol,1995,34(2):235-241
[59]Gillet JP, Efferth T, Steinbach D, et al.Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res.2004 Dec 15:64(24):8987-93.
[60]Kumar A, Soprano DR, Parekh HK. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Cancer Res.2001 Oct 15:61(20):7552-5
[61]Biedler JL. Genetic aspects of multidrug resistance. Cancer,1992,70 (6 Suppl):1799-1809
[62]Dumontet C, Duran GE, Steger KA, et al. Resistance mechanisms in human sarcoma mutants'derived by single-step exposure to paclitaxel (Taxol).Cancer Res,1996,56(5):1091-1097
[63]Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking MDR1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A,1997,94(8):4028-4033
[64]Childs S, Yeh RL, Hui D, et al. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res,1998,58(18):4160-4167
[65]Kavallaris M. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anti-cancer Drugs,1997, 8(1):17-25
[66]Ohta SK, Nishio N, Kubota T, et al. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res, 1994,85(3):290-297
[67]Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest,1997,100(5):1282-1293
[68]Juliano RL, Ling VA. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys
Acta,1976,455(1):152-162
[69]Riordan JR, Deuchars K, Kartner N, et al. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines Nature,1985,316 (6031):817-819
[70]Kartner N,Evernden-Porelle D,Bradley G, et al. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature,1985,31 (6031):820-823
[71]Roninson IB, Chin JE, Choi K, et al. Isolation of human MDR DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA,1986,83(12):4538-4542
[72]Atul Kumar, Dianne R Soprano, Hemant K Parekh. Cross-Resistance to the Synthetic Retinoid CD437 in a Paclitaxel-resistant Human Ovarian Carcinoma Cell L ine Is Independent of the Overexpression of Retinoic Acid Receptor-γ 1. Cancer Res,2001,61(20):7552-7555
[73]Kang HC, Kim IJ, Park JH, et al. Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays. Clin Cancer Res,2004,10(1Pt1):272-284
[74]Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995, 332(15):1004-1014
[75]Yu LJ, Matias J, Scudiero DA, et al. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos,2001, 29(3):304-312
[76]Stein U, Walther W, Lauren M, et al. Tumor necrosis factor alpha and expression of the multidrug resistance-associated genes LRP and MRP. JNCI.1997,89(11):807-813
[77]Alphonse G, Bionda C, Aloy MT, et al. Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels. Oncogene,2004,23(15):2703-2715
[78]Roy S, Bayly CI, Gareau Y, et al. Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc Natl Acad Sci USA,2001,98(11):6132-6137
[79]Jordan MA, Wilson L. Microtubules and Actin Filaments:Dynamic Targets for Cancer Chemotherapy. Curr Opin Cell Biol,1998,10(1),123-130
[80]Wilson L,Jordan MA.Microtubule dynamics:Taking aim at a moving target. Chem Biol,1995,2(9):569-573
[81]Jordan MA, Wendell K, Gardiner S, et al.Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res,1996,56(4):816-825
[82]Rao S, Krauss NE, Heerding JM, et al.3'-(p-azidobenzamido) taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem,1994,269(5):3132-3134
[83]Preisler VK, Wuck D, Stopper H, et al. Combination of paclitaxel and radiation:genotoxicity in vitro in four mammalian cell lines. Cancer Lett,1999,145(1-2):29-33
[84]Burkhart CA, Kavallaris M, Band Horwitz S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta, 2001,1471(2):01-9
[85]Jaffrezou JP, Dumontet C, Derry B, et al. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res,1995,7(10-11):517-527
[86]Ranganathan S, Benetatos CA, Colarusso PJ, et al. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer,1998,77(4):562-566
[87]Kavallaris M, Kuo DY, Burkhart CA, et al.Taxol-resistant epithelid ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest,1997,100(5):1282-1293
[88]陈杰,钱桂生,黄桂君,等.人肺腺癌多药耐药细胞系的建立及其生物学特征.第三军医大学学报,2001,23(2)：135-137
[89]Baeniziger NL, Brodic GN. Majerus PW. A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci,1971,68(1):240-243
[90]Lawler J, Hynes RO. The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol,1986,103(5):1635-1648
[91]Liu P, Wang Y, Yang RC, et al. Adenovirus-mediated gene therapy with all antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leuk Res,2003,27(8):701-708
[92]Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospon-din-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol,1999,155(2):441-452
[93]Miao WM, Seng WL, Duquette M, et al.Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res,2001,61 (21):7830-7839
[94]Rofstad EK, Henriksen K, Galappathi K, et al. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res,2003, 63(14):4055-4061
[95]Li K,Yang M, Yuen PM, et al.Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and caspase-3. Int J Mol Med,2003,12(6):995-1001
[96]Luo JC, Yamaguchi S,Shinkai A, et al. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res,1998,58(12):2652-2660
[97]Dameron KM, Volpert OV, Tainsky MA, et al. Control of an giogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science,1994, 265(5178):1582-1584
[98]Peng X, Li W, Tan G. Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression. Anticancer Drugs,2010,21 (4):381-388
[1]杨纯正.肿瘤细胞耐药基因研究进展.中国肿瘤,1996,5(7)：15
[2]Shen DW, FojoA, Chin JE, et al. Human multidrug-resistant cell lines: increased MDR1 expression can precede gene amplification. Science (Wash DC),1986,232(4750):643-645
[3]Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer:role of ATP-dependent transporters. Nat Rev Cancer,2002,2(1):48-58
[4]Shen DW, Goldenberg S, Pastan I, et al. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol,2000,183(1):108 -116
[5]Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol,1996,49(2): 311-318
[6]Goto S, Kamada K, Soh Y,et al.Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res, 2002,93 (9):1047-1056
[7]Urasaki Y, Laco GS, Pourquier P, et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res,2001,61 (5):1964-1969
[8]Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res,1996,56(21):4881-4886
[9]Lin X, Ramamurthi K, Mishima M, et al. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res,2001, 61(4):1508-1516
[10]Taverna P, Liu L, Hanson AJ, et al. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol,2000,46(6):507-516
[11]Hott a T, Saito Y, Mikami T, et al. Interrelationship between 06-alkylguanine-DNA alkyltransferase activity and susceptibility to chloroethylnitrosoureas in several glioma cell lines.J Neurooncol, 1993,17(1):1-8
[12]Shiloh Y. ATM and ATR:networking cellular responses to DNA damage. Curr Opin Genet Dev,2001,11(1):71-77
[13]Watanabe T, Tsuge H, Oh-Hara T, et al. Comparative study on reversal efficacy of SDZ PSC 833, Cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol,1995,34(2):235-241
[14]胡振.肿瘤多药耐药逆转剂的研究进展.药学进展,2002,26(3)：129-133
[15]Tsuruo T, Iida H, Tsukagoshi S,et al. Overcoming of Vincristine Resistance in P388 Leukemia in Vivo and in Vitro through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil. Cancer Res,1981,41 (5):1967-1972
[16]Solary E, Velay I, Chauffert B, et al. Quinine Circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR. Nouv Rev Fr Hematol,1990,32(5):361-363
[17]Solary E, Caillot D, chauffert B, et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and Cytarabine for the treatment of acute leukema. J Clin Oncol,1992,10 (5):1730-1735
[18]Watanabe T, Tsuge H, Oh-Hara T, et al. Comparative study on reversal efficacy of SDZ PSC 83, Cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol,1995,34(2):235-241
[19]Kirk J, Syed SK. Harris AL. et al. Reversal of P-glycoprotien mediated muhidrug resistance by pure antioestrogens and novel tamoxifen derivatives. Biochem Pharmacol,1994,48:277-282
[20]谭伟欣,黄永明,刘金文.MRP1介导的多药耐药及其逆转剂的研究进展.广东医学,2006,27(9)：1418-1420
[21]CHEN B, JIN F, LU XL, et al. Effect of PKC inhibitor on P-gp expression and drug-resistance in MGC803 cells. Ai Zheng,2004,23:396-400.
[22]Burg D, Filippov DV, Hermanns R, et al. Peptidomimetic glutathione analogues as novel γGT stable GST inhibitors. J Bioorg Med Chem, 2002,10 (1):195-205
[23]Silva KL, Vasconcelos FC, Marques-Santos LF, et al. CPT-11 induced cell death in leukemic cells is not affected by the MDR phenotype. Leuk Res,2003,27 (3):243-251
[24]Wilson WH, Bates S, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol,1995,13 (8):1995-2004
[25]Pascaud C, Garrigos M, Orlowski S. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J.1998,15,333 (Pt 2):351-358
[26]Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T. Comparative study on reversal efficacy of SDZ PSC833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo Acta Oncol. 1995,34(2):235-341
[27]Lo YL, Liu FI, Yang JM, et al. Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid. Anti Cancer Res,2001,21 (1A):445-450
[28]孙士勇,韩锐.谷胱甘肽S-转移酶与肿瘤防治.国外医学药学分册,1992,19(2)：66-71
[29]胡军,赵瑾瑶,杨佩满,等.β-榄香烯乳剂逆转多药耐药细胞株MCF-7/ADM对阿霉素耐药性研究.中国微生物学杂志,2003,14(4)：214-215
[30]关松磊.关于卵巢癌的蛋白质组学和姜黄素的体外抑制研究：[硕士学位论文].吉林：吉林大学药学院,2007
[31]徐峰,蔡卓夫.肿瘤耐药逆转剂研究进展.中南药学,2004,2(5)：301- 303
[32]王宝成,郭军,顾广玉,等.切割MDR1 RNA的核酶(Ribozyme)对肝癌多药耐药细胞株BEL-7402/DOX化疗耐药性的逆转作用.中国肿瘤生物治疗杂志,1997,4(2)：106-109
[33]Huesker M, Folmer Y, Schneider M, et al. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes. Hepatology,2002,36 (4 Pt1):874-884
[34]Kostenko EV, Laktionov PP, Vlassov VV, et al. Downregulation of PGY1/ MDR1 mRNA level in human KB cells by antisense oligonucleotide conjugates:RNA accessibility in vitro and intracellular antisense activity. Biochim Biophys Acta,2002,1576 (1-2):143-147
[35]Nieth C, Priebsch A, Stege A, et al. Modulation of the classical multi drug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett, 2003,545 (2-3):144-150
[36]Caldas H, Holloway MP, Hall BM, et al. Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo. Med Genet,2006,43 (2):119-128
[37]Yuan J, Kramer A, Matthess Y, et al. Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene,2006,25 (12):1753-1762
[38]Zou W, Yang H, Hou XH, et al. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett,2007,248 (2):211-218
[39]Pichler A, Zelcer N, Prior JL, et al. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res,2005,11 (12): 4487-4494
[40]Duan ZF, Katherine AB, Michael VS. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther, 2004,3 (7):833-838
[41]Anke W, Alexandra S, Yutaka M, et al. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther,2004, 11 (11):699-706
[42]Sun YL, Zhou GY, Li KN, et al. Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells. Neoplasma,2006,53 (1):1-8
[43]Kankesan J, Vanama R, Yusuf A, et al. Effect of P53, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats. Carcinogenesis,2004,25 (3):425-430
[44]Rago RP, Einstein A Jr, Lush R, et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol,2003,51 (4):297-305
[45]Bentires AM, Barbu V, Fillet M, et al. NF-kappa B transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene,2003,22 (1):90-97
[46]Minderman H,O'Loughlin KL, Pendyala L, et al. VX-710 (Biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-Glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res,2004,10 (5): 1826-1834
[47]魏志霞,田韧,端木中.α-干扰素对肝癌多药耐药株SMMC-7221/ADM的逆转及其机制研究.临床肿瘤学杂志,2001,6(4)：339-341
[48]Ghetie MA, Marches R, Kufert S, et al. An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line. Blood,2004,104 (1): 178-183
[49]Ghetie MA, Crank M, Kufert S, et al. Rituximab but not Other anti-CD20 Antibodies Reverses Multidrug Resistance in 2 B lymphoma Cell Lines, Blocks the Activity of P-glycoprotein (P-gp), and Induces P-gp to Translocate out of Lipid Rafts. J Immunother(1997),2006,29 (5): 536-544
[50]Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22 Characterization of in Vitro Properties. Clin Cancer Res,2003,9 (10):3982-3990
[51]Holliger P, Prospero T, Winter G. "Diabodies" : small bivalent antibody fragment. Cancer Immunol Immunother,1997,45 (2):128-130
[52]Zhu ZP, Zapata G, Shalaby R, et al. High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology,1996,14 (2):192-196
[53]Xu YF, Yang CZ, Zhu ZP. Bispecific antibody and its clinical application in cancer. Chinese Science Bulletin,2001,46 (5):353-358
[54]秦岚,赵艳津,高瀛岱,等.抗P-gp/抗CD3微型双功能抗体在小鼠体内性质的研究.天津医药,2006,34(9)：625-627
[55]Niethammer AG, Wodrich H, Loeffier M. Multidrug Resistance-1(MDR-1):a new target for T cell-based immunotherapy FASEB J,2005,19 (1):158-159
[56]Kolberg A, Rosa TG, Puhl MT, et al. Low expression of MRP1/GS-X pump ATPase in lymphocytes of Walker 256 tumour-bearing rats is associated with cyclopentenone prostaglandin accumulation and cancer immunodeficiency. Cell Biochem Funct,2006,24 (1):23-25
[57]Rago RP, Einstein AJR, Lush R, et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol,2003,51 (4):297-305
[58]Atkins MB, Regan M, Mc DD. Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma. Cancer Res,2004,10 (18):6342s-6346s
[59]Marks DC, BelovL R, Davey MW, et al. The MTT cell viability assay for cytotoxicity testing in multidrug-resistance human Leukemic ceils. Leuk Res,1992,16 (12):1165-1173
[60]Azuma E, Masuda S, Qi J, et al. Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias. Eur J Haematol,1997,59 (3):14-19
[61]Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase Ⅰ is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol,2004,10 (8):1146-1151
[62]冷卫东,王大章,冯戈,等.热疗对舌鳞癌Tca8113细胞及其耐药细胞株耐药性的影响.华西口腔医学杂志,2006,24(5)：447-450
[63]Walther W, Arlt F, Fichtner I, et al. Heat-inducible in vivo gene therapy of colon carcinoma by human MDR1 promoter-regulated tumor necrosis factor-alpha expression. Mol Cancer Ther,2007,6 (1):236-243
[64]邢益阳.中药逆转肿瘤多药耐药的研究进展.中医药临床杂志,2007,19(1)：91-93
[65]李宏建,李贵海,孙付军,等.苦参碱对肿瘤细胞获得性多药耐药的逆转作用.中国医院药学杂志,2005,25(5)：389-391
[66]Choi SU, Park SH, Kim KH. The bisbenzylisoquinoline aloids, tetran dine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anti Cancer Drugs,1998,9 (3):255-261
[67]Yoshikawa M, Ikegami Y, Hayasaka S, et al. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer,2004,110 (6):921-927
[68]Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550:a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res,2001,7 (5):1429-1437
[69]Minderman H, Brooks T, O' Loughlin KL, et al. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel and tRA96023. Cancer Chemotherapy and Pharmacology,2004,53 (5):363-369
[70]Ojima I, Chen J, Sun L, et al. Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem,2008,51 (11): 3203-3221
[71]Aoki Y, Kurata H, Watanabe M, et al. Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer. Am J Clin Oncol 2004; 27 (5):461-464
[72]Peng X, Li W, Tan G. Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression. Anticancer Drugs,2010,21 (4):381-388